Tuzistra XR for cough relief is said to be the only twice-daily, extended-release codeine-based cough and cold syrup available in the US.
Vernalis and Tris Pharma announced that Tuzistra XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral suspension, CIII (DEA Schedule III) is now available to patients and physicians in the United States.
FDA approved the extended-release formulation in April 2015 for the relief of cough, common cold, and symptoms associated with upper respiratory allergies in adults. Tuzistra XR is said to be the only codeine-based extended-release cough cold syrup available in the US.
The US cough cold prescription market has been valued at more than $3 billion, with 30–35 million annual prescriptions. This market is dominated by short-acting treatments, which require dosing four to six times a day.
Tuzistra XR was developed using Tris Pharma's liquid sustained release technology, LiquiXR, which allows for extended drug delivery throughout a 12-hour dosing period.
Source: Vernalis
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.